BackProcaps Group S.A Overview

Procaps Group S.A Total Revenue

Latest total revenue for PROC: $410M, below the Healthcare sector average of $110B.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

$118.41M
7.25% YoY

As of Sep 2023

Annual Revenue (TTM)

$414.10M
4.8% YoY

Trailing 12 months ending Sep 2023

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

Procaps Group S.A (PROC) FAQ

The latest total revenue for PROC is $410M as of September 2023. That compares with $430M in the prior-year period — down 4.8% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Procaps Group S.A's historical trend and sector peers before judging valuation or financial health.

Over the past year, PROC's total revenue moved from $430M to $410M — a 4.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Procaps Group S.A's operating scale or balance-sheet position.

Against Healthcare companies, PROC currently prints $410M for total revenue, while the sector average sits near $110B. That is roughly 99.6% below the sector mean. Large gaps often invite a closer look at Procaps Group S.A's growth, margins, and balance sheet.

A total revenue figure of $410M for PROC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting PROC's total revenue ($410M), review year-over-year change from $430M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.